6833.HK Stock Analysis
68
Uncovered
Sinco Pharmaceuticals Holdings Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Sinco Pharmaceuticals Holdings Ltd. engages in the marketing, promotion, and channel management services for pharmaceutical products and medical devices. The company is headquartered in Chengdu, Sichuan and currently employs 133 full-time employees. The company went IPO on 2016-03-10. The company provides its integrated MPCM services to small- and medium-sized overseas pharmaceutical manufacturers that do not possess independent marketing and promotion capabilities in China. Its major product is human albumin solution, a human albumin product manufactured by Octapharma, which is used to remedy hypovolemia and hypovolemic shock, abnormally high intracranial pressure, edema and ascites, and to prevent and cure hypoalbuminemia and neonatal hyper-bilirubinemia. In addition, its products include axetine, medocef, esafosfina, tad and taurolite.